Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more

Recent & Breaking News (TSXV:NRX)

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

GlobeNewswire 3 days ago

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

GlobeNewswire May 17, 2024

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

GlobeNewswire April 25, 2024

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

GlobeNewswire April 19, 2024

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

GlobeNewswire April 2, 2024

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

GlobeNewswire March 27, 2024

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

GlobeNewswire March 22, 2024

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

GlobeNewswire March 15, 2024

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

GlobeNewswire March 8, 2024

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

GlobeNewswire March 1, 2024

NurExone's Intellectual Property Portfolio Expands

GlobeNewswire February 20, 2024

NurExone Launches Licensing Efforts for ExoTherapy Platform

GlobeNewswire February 14, 2024

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

GlobeNewswire February 2, 2024

Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)

TheNewsWire January 22, 2024

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

GlobeNewswire January 17, 2024

NurExone Biologic closes private placement of nearly C$2M

Jim Wilkie January 5, 2024

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

GlobeNewswire January 5, 2024

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

GlobeNewswire November 29, 2023

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 24, 2023

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

GlobeNewswire October 30, 2023